The present and future control of pertussis

Clinical Infectious Diseases

Volumn 51, Issue 6, 2010, Pages 663-667

  Cherry, James D ^a  

^a MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEMAGGLUTININ; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PERTACTIN; PERTUSSIS TOXIN;

ADULT; AGED; ANTIBODY TITER; BORDETELLA PERTUSSIS; DIPHTHERIA; DRUG EFFICACY; FIMBRIA; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MORBIDITY; MORTALITY; NOTE; PERTUSSIS; PRIORITY JOURNAL; TETANUS; VACCINE FAILURE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; UNITED STATES; WHOOPING COUGH; YOUNG ADULT;

EID: 77955932507     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/655826     Document Type: Note

References (37)

1. Kretsinger K, Broder KR, Cortese MM, et al; Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices, Healthcare Infection Control Practices Advisory Committee. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infectioun Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Morb Mortal Wkly Rep 2006; 55(RR-17):1-37.
2. Mertsola J, Van Der Meeren O, He Q, et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis 2010; 51(6):656-662 (in this issue).
3. McNabb SJ, Jajosky RA, Hall-Baker PA, et al; Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 2006. MMWR Morb Mortal Wkly Rep 2008; 55:68, 77, 83.
4. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005; 18:326-382.
5. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005; 115:1422-1427.
6. Cherry JD. Epidemiology of pertussis. Pediatr Infect Dis J 2006; 25:361-362.
7. Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J 2005; 24:S10-S18.
8. Cherry JD. The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. Curr Probl Pediatr 1984; 14:1-78.
9. Cherry JD, Brunell PA, Golden GS, Karson DT. Report of the task force on pertussis and pertussis immunization-1988. Pediatrics 1988; 81:939.
10. Mink CM, Cherry JD, Christenson P, et al. A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992; 14: 464-471.
11. Cherry JD, Heininger U. Pertussis and other Bordetella infections. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL, eds. Feigin & Cherry's textbook of pediatric infectious diseases. 6th ed. Vol 1. Philadelphia: WBSaunders, 2009:1683-1706.
12. Marchant CD, Loughlin AM, Lett SM, et al. Pertussis in Massachusetts, 1981-1991: incidence, serologic diagnosis, and vaccine effectiveness. J Infect Dis 1994; 169:1297-1305.
13. Stehr K, Cherry JD, Heininger U, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 1998; 101: 1-11. (Pubitemid 28030315)
14. Schmitt HJ, Wirsing von Konig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996; 275:37-41.
15. Liese JG, Meschievitz CK, Harzer E, et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J 1997; 16:1038-1044.
16. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997; 15: 1606-1612.
17. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H, and the Ad Hoc Group for the Study of Pertussis Vaccines. Randomised controlled trial of two-component, threecomponent, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 1997; 350:1569-1577.
18. Mannerstedt G. Pertussis in adults. J Pediatr 1934; 5:596-600.
19. Cherry JD. Pertussis in the preantibiotic and prevaccine era, with emphasis on adult pertussis. Clin Infect Dis 1999; 28:S107-S111.
20. Cherry JD. The role of Bordetella pertussis infections in adults in the epidemiology of pertussis. In: Brown F, Greco D, Mastrantonio P, Salmaso S, Wassilak S, eds. Pertussis vaccine trials. Basel, Switzerland: Karger, 1997:181-186.
21. Cherry JD, Beer T, Chartrand SA, et al. Comparison of values of antibody to Bordetella pertussis antigens in young German and American men. Clin Infect Dis 1995; 20:1271-1274.
22. Versteegh FGA, Schellekens JFP, Nagelkerke AF, Roord JJ. Laboratory-confirmed reinfections with Bordetella pertussis. Acta Paediatr 2002; 91:95-99.
23. de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect 2006; 53:106-113.
24. Strebel P, Nordin J, Edwards K, et al. Population- based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J Infect Dis 2001; 183:1353-1359.
25. Ward JI, Cherry JD, Chang SJ, et al. Bordetella pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized acellular pertussis vaccine trial (APERT). Clin Infect Dis 2006; 43:151-157.
26. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? Pediatr Infect Dis J 2004; 23:985-989.
27. Wendelboe AM, Njamkep E, Bourillon A, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007; 26: 293-299.
28. Kowalzik F, Barbosa AP, Fernandes VR, et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis J 2007; 26:238-242.
29. Crowcroft NS, Booy R, Harrison T, et al. Severe and unrecognized: pertussis in UK infants. Arch Dis Child 2003; 88:802-806.
30. De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000; 182:174-179.
31. Cherry JD. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin Infect Dis 1999; 28(suppl 2):S112-S117.
32. Mertens PLJM, Stals FS, Schellekens JFP, Houben AW, Huisman J. An epidemic of pertussis among elderly people in a religious institution in The Netherlands. Eur J Clin Microbiol Infect Dis 1999; 18:242-247.
33. Holmes WH. Whooping-cough or pertussis. In: Holmes WH, ed. Bacillary and rickettsial infections: acute and chronic. New York, NY: Macmillan, 1940:394-414.
34. Cherry JD. Pertussis in adults. Ann Intern Med 1998; 128:64-66.
35. Cherry JD. 'Pertussis vaccine encephalopathy': it is time to recognize it as the myth that it is. JAMA 1990; 263:1679-1680.
36. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16:1907-1916.
37. Le T, Cherry JD, Chang SJ, et al. Immune responses and antibody decay following immunization of adolescents and adults with an acellular pertussis vaccine: APERT study. J Infect Dis 2004; 190:535-544.